Welcome to our dedicated page for Medifast news (Ticker: MED), a resource for investors and traders seeking the latest updates and insights on Medifast stock.
Medifast, Inc. reports developments as a metabolic health and wellness company built around the OPTAVIA science-backed, coach-guided lifestyle system. Its updates center on revenue trends, gross margin, active earning coaches, coach productivity and the company's shift toward metabolic health amid changes in weight-loss demand and GLP-1 medication adoption.
Recurring company news also covers OPTAVIA program evidence, nutrition and habit-creation offerings, HSA/FSA reimbursement availability on select insurance plans, independent coach community initiatives, media content tied to metabolic health, and governance matters such as board nominations and stockholder cooperation agreements.
Medifast (NYSE: MED) launched the Medifast Metabolic Health Institute (MMHI), a centralized body to advance metabolic health through research and evidence-based education. The institute consolidates 45 years of Medifast clinical work, including more than 100 peer-reviewed presentations and publications, 18 randomized controlled trials, and over 30 scientific studies and analyses.
MMHI underpins Metabolic Synchronization®, the science behind the Trilivy™ metabolic health system, and sets scientific and educational standards for Trilivy Coach Certification. Leadership includes MMHI Distinguished Fellow Dr. Wayne Scott Andersen, the Medifast Scientific Advisory Board, and the Scientific & Clinical Affairs and R&D teams.
Medifast (NYSE: MED) reported second quarter 2026 revenue of $76.4 million, down 27.6% from $105.6 million a year earlier, reflecting a 48.7% decline in independent active earning coaches to 11,700. Average revenue per active earning coach rose 41.0% to $6,529.
Gross profit was $53.4 million with a 69.9% margin, while SG&A fell 25.7% to $57.7 million but increased to 75.6% of revenue. Medifast posted a net loss of $3.1 million, or $0.28 per diluted share, versus net income of $2.5 million, or $0.22 per share, in Q2 2025.
The company ended the quarter with $169.8 million in cash, cash equivalents and investment securities and no debt, and working capital of $160.5 million. Medifast launched its Trilivy Reset product line, its Metabolic Health Institute, and initiated its Catalyst cost‑saving program. 2026 revenue guidance is $270–$300 million with a full‑year loss per share of $0.25–$1.75.
Medifast (NYSE: MED) will release financial results for the quarter ended June 30, 2026, on Monday, August 3, 2026, after market close. A conference call with CEO Nick Johnson and CFO Jim Maloney will follow at 4:30 p.m. ET, webcast via Medifast’s investor relations site and phone.
Medifast (NYSE:MED) appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. He succeeds Dan Chard, who will remain Chairman of the Board and stay actively involved.
The move follows a previously disclosed leadership transition plan and reflects Board confidence in Johnson’s leadership and Medifast’s strategic direction.
Medifast (NYSE: MED) reported Q1 2026 results for the quarter ended March 31, 2026. Revenue was $76.0 million, down 34.3% YoY; independent active earning coaches totaled 14,000, down 44.9% YoY. Net loss was $2.1 million ($0.19 per diluted share). Cash, cash equivalents, and investment securities were $168.9 million with no debt. Management noted higher revenue per coach and continued transformation toward metabolic health; full-year 2026 revenue guidance is $270M–$300M with loss per share guidance of $1.55–$2.75.
Medifast (NYSE: MED) will announce financial results for the quarter ended March 31, 2026 on Monday, May 4, 2026 after market close. The company will host a live conference call at 4:30 p.m. ET on May 4, 2026 to discuss results.
Company participants include Dan Chard (CEO), Nick Johnson (President), and Jim Maloney (CFO). The call will be webcast on the investor relations website and archived online through August 4, 2026. Telephone dial-in and a telephonic playback (May 4–11, 2026) are available with access code 13759893.
Medifast (NYSE: MED) entered a Cooperation Agreement with Steamboat Capital, which beneficially owns above 5% of outstanding shares, and agreed to nominate Parsa Kiai and Jeff Rose as independent director candidates for the May 19, 2026 annual meeting.
Medifast’s board determined directors Jeffrey Brown and Michael Hoer will not stand for reelection. CEO Dan Chard will step down on June 1, 2026, with President Nicholas Johnson expected to succeed him. The agreement includes customary standstill and voting provisions through the 2027 annual meeting.
Medifast (NYSE: MED) announced that OPTAVIA’s metabolic health system is now eligible for reimbursement on select insurance plans using HSA/FSA funds, potentially letting clients save up to 40% on program costs.
The company cites Metabolic Synchronization science and a clinical result showing 98% lean mass retained and a 14% reduction in visceral adiposity at 16 weeks, and plans a new product system launch in 2026.
Medifast (NYSE: MED) reported Q4 2025 revenue of $75.1M and full-year 2025 revenue of $385.8M, with Q4 net loss of $18.1M and full-year net loss of $18.7M. Cash and investment securities totaled $167.3M with no debt. Active earning coaches declined to 16,100, while revenue per active coach rose to $4,664. The company established a $12.1M non-cash valuation allowance against deferred tax assets, which materially affected EPS.
Medifast provided 2026 revenue and EPS ranges and reinstated guidance as it executes a transformation toward metabolic health offerings.
Medifast (NYSE: MED) will announce financial results for the quarter and full year ended December 31, 2025, on Tuesday, February 17, 2026 after market close.
The company will host a conference call at 4:30 p.m. ET with CEO Dan Chard, President Nick Johnson, and CFO Jim Maloney. The call will be webcast and archived through May 17, 2026. Telephone and playback dial-in details are provided for listeners.